Clearmind Medicine Inc. CMND
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -95.76%
- 1 year
- -99.76%
- Open
- 6.02
- Prev close
- 6.50
- Mkt cap
- 3.12M
- Vol
- 1.83K
- Avg vol
- 57.83K
- EPS
- -461.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.02
- High
- 6.14
- Forward P/E
- 0.00
- Beta
- -1.51
- Short ratio
- 1.88
- Inst. own
- 16.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.39
- 200-d avg
- 1.33
- 1y target
- 0.00
1Y chart
Events in this range
- Dec 15, 2025Split: 1 for 40
- May 21, 2026Split: 1 for 10
- Oct 5, 2026Split: 1 for 8
Signals (22)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| RSI: Oversold | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| RSI: Oversold | Jul 21, 2026 | 3 months ago |
| RSI: Oversold | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| RSI: Oversold | May 27, 2026 | 5 months ago |
| RSI: Oversold | May 19, 2026 | 5 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 20, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 16, 2026 | 6 months ago |
| SMA: Bearish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 7, 2026 | 6 months ago |
| RSI: Oversold | Mar 9, 2026 | 7 months ago |
| RSI: Oversold | Mar 5, 2026 | 8 months ago |
| RSI: Oversold | Feb 3, 2026 | 9 months ago |
| RSI: Oversold | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 3, 2025 | 11 months ago |
Newest 20 of 22.
Key statistics
- Market cap
- 5.35M
- Enterprise value
- -2.75M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.40
- EPS (TTM)
- -1.23
- Beta
- -1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 162.86K
- Total cash
- 7.68M
- Total debt
- 60.90K
- Return on equity
- -267.90%
- Shares outstanding
- 4.38M
- Short % of float
- 4.72%
- 50-day average
- 1.39
- 200-day average
- 1.33
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Clearmind Medicine Inc.
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders; and Dr. Glitter Pty Ltd to develop and commercialize the MEAI-based alcohol substitute and ActivCrystal technology. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- clearmindmedicine.com
News
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
- Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
- Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform
- Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia
- Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026
- Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide
- Clearmind Medicine Says Yale University’s IRB Approves Initiation Of Patient Recruitment For Parts B And C Of Phase I/II Clinical Trial Evaluating CMND‑100
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on CMND — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gotham Asset Management, LP | 10.70% | 339,008 | 413.59K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 5.38% | 170,641 | 208.18K | Sep 29, 2024 |
| UBS Group AG | 4.46% | 141,337 | 172.43K | Sep 29, 2024 |
| Cornerstone Wealth Group, LLC | 0.63% | 20,000 | 24.40K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.56% | 17,729 | 21.63K | Sep 29, 2024 |
| HRT Financial LP | 0.40% | 12,756 | 15.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 6.74% | 213,764 | 260.79K | Oct 30, 2024 |